These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Atherogenic dyslipidemia and residual risk. State of the art in 2014]. Millán Núñez-Cortés J; Pedro-Botet Montoya J; Pintó Sala X; Clin Investig Arterioscler; 2014; 26(6):287-92. PubMed ID: 25450326 [TBL] [Abstract][Full Text] [Related]
11. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). ; Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL Atherosclerosis; 2016 Oct; 253():281-344. PubMed ID: 27594540 [No Abstract] [Full Text] [Related]
12. [Dyslipidaemia and vascular risk. A new evidence based review]. Pallarés-Carratalá V; Pascual-Fuster V; Godoy-Rocatí D Semergen; 2015; 41(8):435-45. PubMed ID: 25559484 [TBL] [Abstract][Full Text] [Related]
14. Non-HDL cholesterol as a therapeutic goal. Brea A; Hernández-Mijares A; Millán J; Ascaso JF; Blasco M; Díaz A; Mantilla T; Pedro-Botet JC; Pintó X Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():28-33. PubMed ID: 31806265 [TBL] [Abstract][Full Text] [Related]
15. Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. Parhofer KG Atheroscler Suppl; 2015 May; 18():109-11. PubMed ID: 25936313 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Sniderman A; Couture P; de Graaf J Nat Rev Endocrinol; 2010 Jun; 6(6):335-46. PubMed ID: 20421882 [TBL] [Abstract][Full Text] [Related]
17. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D; Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445 [No Abstract] [Full Text] [Related]
18. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Plana N; Ibarretxe D; Cabré A; Ruiz E; Masana L Clin Investig Arterioscler; 2014; 26(6):274-84. PubMed ID: 24931442 [TBL] [Abstract][Full Text] [Related]